- Investing.com
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Metrics to compare | DAWN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDAWNPeersSector | |
---|---|---|---|---|
P/E Ratio | −7.3x | −1.8x | −0.5x | |
PEG Ratio | −0.14 | −0.07 | 0.00 | |
Price/Book | 1.5x | 2.9x | 2.6x | |
Price / LTM Sales | 3.7x | 64.4x | 3.3x | |
Upside (Analyst Target) | 292.4% | 305.7% | 42.8% | |
Fair Value Upside | Unlock | 10.9% | 6.5% | Unlock |